Viewing Study NCT07281833

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:51 AM
Ignite Modification Date: 2026-03-02 @ 4:04 PM
Study NCT ID: NCT07281833
Status: RECRUITING
Last Update Posted: 2025-12-15
First Post: 2025-11-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
Sponsor: West German Study Group
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None HR-positive Breast Cancer View
None Advanced Breast Cancer View
None Metastatic Breast Cancer View
None HER2-negative Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None breast cancer View
None advanced, metastatic View
None metastatic View
None progression View
None HR+ View
None HER2- View
None capivasertib View
None eHealth View
None ePRO View